Empagliflozin Fails to Reduce Events After Acute MI

Empagliflozin did not significantly reduce overall HF hospitalization or all-cause death in high-risk patients in EMPACT-MI but did reduce first and total hospitalizations.

Related Keywords

New York ,United States ,Texas ,Dallas ,James Januzzi ,Deepak Bhatt ,Valentin Fuster ,Carine Hamo ,Michelle Albert ,Javed Butler ,Baylor Scott White Research Institute ,American College Of Cardiology ,Grossman School Of Medicine ,Leonh Charney Division Of Cardiology ,Department Of Medicine ,American College ,Scientific Sessions ,New England Journal ,Baylor Scott ,White Research Institute ,Mount Sinai Heart ,Icahn School ,Mount Sinai Health System ,New York City ,Lancet Diabetes ,Myocardial Infarction ,Heart Failure ,Sglt2 Inhibitors ,Odium Glucose Transporter 2 Inhibitors ,Odium Glucose Co Transporter 2 Inhibitors ,Sodium Glucose Cotransporter 2 Inhibitors ,Diabetes Mellitus Type 2 ,Iabetes Mellitus Type Ii ,Type 2 Diabetes ,Ype 2 Dm ,T2dm ,2d ,Chronic Renal Failure Kidney Ckd Disease ,Renal Failure ,